share_log

American Aires Closes $4 Million Oversubscribed Private Placement

American Aires Closes $4 Million Oversubscribed Private Placement

美國艾利斯完成400萬美元超額認購私募配售
newsfile ·  02/17 08:11

Toronto, Ontario--(Newsfile Corp. - February 16, 2024) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) ("Aires" or the "Company"), a company focused on scientifically-proven EMF modulation technology, announces the closing of its non-brokered private placement offering (the "Offering") of 26,666,663 units of the Company (the "Units") at a price of $0.15 per Unit (the "Offering Price") for aggregate gross proceeds of approximately $4,000,000. Each Unit is comprised of one common share in the Company (each, a "Common Share") and one common share purchase warrant (each, a "Warrant") being exercisable into one Common Share at a price of $0.25 per share for a period of 24 months from closing of the Offering, provided that, in the event that the volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the "CSE") exceeds $0.40 for a period of 10 consecutive trading days, the Company will have the right to accelerate the expiry date to 30 days following the date on which the Company provides notice thereof to the holders of the Warrants (the "Accelerated Expiry").

安大略省多倫多--(Newsfile Corp.,2024 年 2 月 16 日)——美國艾利斯公司(CSE:WIFI)(場外交易鏈接:AAIRD)(”艾利斯“或者”公司“)是一家專注於經過科學驗證的EMF調製技術的公司,宣佈結束其非經紀私募發行(”提供“) 本公司 26,666,663 個單位(”單位“) 以每件商品的價格爲 0.15 美元(”發行價格“)總收益約爲400萬美元。每個單位由公司的一股普通股組成(每個單位爲”普通股“) 和一份普通股購買認股權證(每份,一份”搜查令“)可以在發行結束後的24個月內以每股0.25美元的價格行使一股普通股,前提是如果加拿大證券交易所普通股的交易量加權平均交易價格(”案例“)在連續10個交易日內超過0.40美元,公司將有權將到期日縮短至自公司向認股權證持有人發出通知之日起的30天(”加速到期“)。

Josh Bruni, CEO of the Company, stated: "We are immensely gratified by the market's strong response to our private placement offering, which was significantly oversubscribed, highlighting the overwhelming interest and confidence in American Aires and our dedicated team. This success not only underscores our investors' belief in our transformative technology but also our dedication to advancing well-being and environmental safety. With this support, we are poised to accelerate our global growth, deepen our scientific research, and extend our impact by venturing into new product categories. We are deeply appreciative of this strong endorsement from the investment community and excited about the future that lies ahead."

該公司首席執行官喬什·布魯尼表示:“我們對市場對我們的私募發行的強勁反應感到非常滿意,該發行被大幅超額認購,這凸顯了人們對美國艾利斯和我們的專業團隊的壓倒性興趣和信心。這一成功不僅凸顯了我們的投資者對我們變革性技術的信念,也凸顯了我們對促進福祉和環境安全的承諾。有了這種支持,我們有望加速全球增長,深化我們的科學研究,並通過涉足新產品類別來擴大我們的影響力。我們對投資界的大力支持深表感謝,並對未來的未來感到興奮。”

In connection with the Offering, the Company paid a cash fee of $47,249.99 to certain arm's length finders, and issued to certain arm's length finders 289,100 non-transferrable finder's warrants, each exercisable to acquire one Unit at a price of $0.15 per Unit for a period for 24 months from the Closing, subject to the Accelerated Expiry.

在本次發行中,公司向某些獨立發現者支付了47,249.99美元的現金費,並向某些獨立發現者發行了289,100份不可轉讓的認股權證,每份認股權證可行使以每單位0.15美元的價格收購一個單位,爲期24個月,視加速到期而定。

The Offering is subject to final approval of the CSE. The securities issued in connection with the Offering are subject to a hold period of four months and one day pursuant to CSE policies and applicable securities laws. The Offering Price was reserved via price protection filed with the CSE on January 15, 2024.

本次發行尚待CSE的最終批准。根據CSE政策和適用的證券法,與本次發行相關的證券的持有期爲四個月零一天。發行價格是通過2024年1月15日向CSE提交的價格保護來保留的。

The combination of the oversubscribed Offering, the improved company valuation and the feedback that the Company has been receiving from investors over the past several months led the management of the Company to believe that the primary objective of the partnership with HUCK Project LLC ("HUCK") announced on August 28, 2023 has been largely achieved. While the Company recognizes that more R&D needs to be done to further solidify our scientific leadership in EMF modulation technology, management is satisfied with how the Company is positioned today as a life sciences firm. This has been and remains the Company's primary objective. The secondary rationale of the HUCK outsourcing partnership was to transfer the inventory financing burden over to HUCK. The Company is pleased to report that this rationale was also successfully addressed through the closing of the $4 million Offering. As a result of the above considerations, the Company no longer views the HUCK partnership necessary and is pleased to announce that it has terminated this partnership with HUCK with both companies retaining a friendly relationship and agreeing to all terms and conditions.

超額認購的發行、公司估值的提高以及公司在過去幾個月中從投資者那裏得到的反饋相結合,使公司管理層相信,與HUCK Project LLC合作的主要目標(”哈克“) 於 2023 年 8 月 28 日宣佈的內容已基本實現。儘管公司認識到,要進一步鞏固我們在電動勢調製技術方面的科學領導地位,還需要進行更多的研發,但管理層對公司當今作爲生命科學公司的定位感到滿意。這一直是並且仍然是公司的主要目標。哈克外包合作伙伴關係的次要理由是將庫存融資負擔轉移給哈克。該公司很高興地報告,通過完成400萬美元的發行,這一理由也得到了成功解決。出於上述考慮,公司認爲不再需要與哈克建立合作伙伴關係,並高興地宣佈,它已終止與哈克的合作伙伴關係,兩家公司保持友好關係並同意所有條款和條件。

Early Warning
On February 16, 2024, prior to the closing of the Offering, Birchtree Investments Ltd. ("Birchtree") disposed beneficial ownership of 6,000,000 Common Shares (the "Disposition"). Prior to the Disposition, Birchtree held 7,062,366 Common Shares, representing 11.9% of the issued and outstanding Common Shares on an undiluted basis (14.6% on a partially-diluted basis). Following the Disposition, Birchtree held 1,062,366 Common Shares, representing 1.8% of the issued and outstanding Common Shares on an undiluted basis (4.8% on a partially-diluted basis). As such, Birchtree ceased to be an insider of the Company. Birchtree participated in the Offering, following which Birchtree held 6,686,953 Common Shares and 7,505,587 common share purchase warrants of the Company. All such warrants contain a restriction on exercise such that Birchtree shall not be permitted to exercise the warrants if it would result in the Common Shares held by Birchtree exceeding 9.9% of the issued and outstanding Common Shares. Birchtree currently does not have any plan to acquire or dispose of additional securities of the Company. However, Birchtree may acquire additional securities of the Company, dispose of some or all of the existing or additional securities it holds or will hold, or may continue to hold its current position, depending on market conditions, reformulation of plans or other relevant factors.

早期警告
2024 年 2 月 16 日,在本次發行結束之前,Birchtree Investments Ltd. (”Birchtree“) 處置了6,000,000股普通股的實益所有權(”處置“)。在處置之前,Birchtree持有7,062,366股普通股,佔未稀釋已發行和流通普通股的11.9%(部分攤薄後爲14.6%)。處置後,Birchtree持有1,062,366股普通股,佔未稀釋已發行和流通普通股的1.8%(部分攤薄後爲4.8%)。因此,伯奇特里不再是公司的內部人士。Birchtree參與了此次發行,隨後Birchtree持有該公司6,686,953股普通股和7,505,587份普通股購買權證。所有這些認股權證都包含行使限制,如果認股權證會導致Birchtree持有的普通股超過已發行和流通普通股的9.9%,則不允許Birchtree行使認股權證。Birchtree目前沒有任何收購或處置公司額外證券的計劃。但是,Birchtree可能會收購公司的更多證券,處置其持有或將要持有的部分或全部現有或額外證券,或可能繼續持有其當前頭寸,具體取決於市場狀況、計劃的重新制定或其他相關因素。

About American Aires Inc.
American Aires Inc. is a Canadian-based nanotechnology company committed to enhancing well-being and environmental safety through science-led innovation, education, and advocacy. Aires has developed proprietary silicon-based microprocessors that reduce the harmful effects of electromagnetic radiation (EMR). Aires' Lifetune products target EMR emitted by consumer electronic devices such as cellphones, computers, baby monitors, and Wi-Fi, including the more powerful and rapidly expanding high-speed 5G networks. Aires is listed on the CSE under the ticker 'WIFI' and on the OTC QB under the symbol 'AAIRF'. Learn more at .

關於美國艾利斯公司
American Aires Inc. 是一家總部位於加拿大的納米技術公司,致力於通過以科學爲主導的創新、教育和宣傳來改善福祉和環境安全。Aires 開發了專有的硅基微處理器,可減少電磁輻射 (EMR) 的有害影響。Aires的Lifetune產品針對手機、計算機、嬰兒監視器和Wi-Fi等消費電子設備發出的EMR,包括功能更強大、擴展速度更快的高速5G網絡。Aires在CSE上市,股票代碼爲 “WIFI”,在場外交易QB上市,股票代碼爲 “AAIRF”。要了解更多,請訪問

On behalf of the board of directors

代表董事會

Company Contact:

公司聯繫人:

Josh Bruni, CEO
Website:

喬什·布魯尼,首席執行官
網站:

Email: wifi@airestech.com
Telephone: (415) 707-0102

電子郵件: wifi@airestech.com
電話: (415) 707-0102

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding CSE approval of the Offering, issuance of securities underlying the Warrants and Finder's Warrants, the Company's ability to solidify its scientific leadership in EMF modulation technology, the Company's position and ability to grow as a life sciences firm, future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Certain material assumptions regarding such forward-looking statements may be discussed in this news release and the Company's annual and quarterly management's discussion and analysis filed at . Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

本新聞稿中列出的某些信息可能包含前瞻性陳述,涉及大量已知和未知的風險和不確定性。除歷史事實陳述以外的所有陳述均爲前瞻性陳述,包括但不限於有關CSE批准本次發行、發行認股權證和Finder認股權證的證券、公司鞏固其在EMF調製技術領域的科學領導地位的能力、公司作爲生命科學公司的地位和成長能力、未來財務狀況、業務戰略、收益用途、企業願景、擬議收購、合作伙伴關係、合資企業和戰略聯盟的陳述,以及合作-公司或涉及公司的運營、預算、成本以及計劃和目標。此類前瞻性信息反映了管理層當前的信念,並基於管理層目前獲得的信息。通常,但並非總是如此,前瞻性陳述可以通過使用 “計劃”、“期望”、“預期”、“預算”、“預期”、“估計”、“預測”、“打算”、“目標”、“目標”、“預期” 或 “相信” 等詞語或此類詞語和短語的變體(包括負面變體)來識別,或者可以用大意爲某些行爲的陳述來識別 “可能”、“可以”、“應該”、“將”、“可能” 或 “將” 被採取、發生或實現。許多已知和未知的風險、不確定性和其他因素可能導致實際業績或業績與前瞻性信息所表達或暗示的任何未來業績或業績存在重大差異。這些前瞻性陳述受到許多風險和不確定性的影響,其中一些風險和不確定性是公司無法控制的,包括但不限於總體經濟狀況、行業狀況和對監管部門批准的依賴的影響。本新聞稿以及公司年度和季度管理層的討論和分析中可能會討論有關此類前瞻性陳述的某些重大假設,網址爲。請讀者注意,編制此類信息時使用的假設雖然在準備時被認爲是合理的,但可能不準確,因此,不應過度依賴前瞻性陳述。除非證券法要求,否則公司不承擔任何更新或修改其前瞻性陳述的義務,無論是由於新信息、未來事件還是其他原因。

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Common Shares, RSUs and Options have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any common shares in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. We seek safe harbour.

沒有任何證券監管機構批准或不批准本新聞稿的內容。普通股、限制性股票單位和期權尚未根據經修訂的1933年《美國證券法》或任何州證券法進行註冊,也不得在美國發行或出售,也不得向美國任何人發行或出售,也不得向美國任何人發行或出售,也不得爲美國任何人的賬戶或利益發行或出售,也不得爲美國任何人的賬戶或利益進行發行或出售。本新聞稿不構成在美國或任何其他司法管轄區的出售要約或要求購買任何普通股的要約,不構成此類要約、招標或出售非法的要約。我們尋求安全的避風港。

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論